Clinical Trial Update: Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and efficacy of activated recombinant human factor VII in cirrhotic patients undergoing partial hepatectomy; study completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bleeding Disorders
• Cirrhosis

Drugs mentioned

• NovoSeven (recombinant coagulation factor VIIa)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Acquired Bleeding Disorder, Cirrhosis | Phase 2 | Status: COMPLETED